Stay updated on ADI-PEG 20 Combo in Advanced GI Cancers Clinical Trial

Sign up to get notified when there's something new on the ADI-PEG 20 Combo in Advanced GI Cancers Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ADI-PEG 20 Combo in Advanced GI Cancers Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the assessment of safety and tolerability of ADI-PEG 20 in combination with FOLFOX in advanced gastrointestinal malignancies, focusing on hepatocellular carcinoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:31:14.000Z thumbnail image
  6. Check
    19 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for Phase 2 HCC subjects, specifying inclusion and exclusion criteria for participants. Previously, this section only indicated that no information was provided.
    Difference
    36%
    Check dated 2024-05-22T20:53:58.000Z thumbnail image
  7. Check
    41 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:36:58.000Z thumbnail image

Stay in the know with updates to ADI-PEG 20 Combo in Advanced GI Cancers Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ADI-PEG 20 Combo in Advanced GI Cancers Clinical Trial page.